AAV1-gamma-sarcoglycan vector(Genethon)

N/A

Report date: 2023/10/26 16:40:53

Base Information

Drug NameAAV1-gamma-sarcoglycan vector(Genethon)

Drug Alias NameGamma sarcoglycanopathy gene therapyAdeno-associated viral 1 vector-mediated gamma-sarcoglycan gene therapyAdeno-associated virus 1-gamma-sarcoglycan gene therapyAAV1-gamma-sarcoglycan gene therapy - GenethonAAV1-gamma-sarcoglycan vector injection +[7]

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector

Mechanisms of ActionGamma-sarcoglycan gene transference

TargetsGamma-sarcoglycan

Therapy Area/IndicationsMuscular Dystrophies, Limb-Girdle

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesViromed

China Registration ClassN/A

Develop Information

Active CompaniesViromed Genethon

Inactive CompaniesN/A

Active IndicationsMuscular Dystrophies, Limb-Girdle

Inactive IndicationsN/A

Other Information

ATC CodeN/A